THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY

被引：0
|
作者：
Nuijten, M. [1 ]
机构：
[1] Ars Accessus Med, Jisp, Netherlands
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [31] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [32] Maintenance Therapy with Pemetrexed after Induction Therapy with Pemetrexed plus Cisplatin for Advanced Pulmonary Adenocarcinoma
    Yum, Ho-Kee
    Park, I-Nae
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S418 - S418
  • [33] Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
    Fan, Yun
    Lin, Neng-ming
    Ma, Sheng-lin
    Luo, Lue-hong
    Fang, Luo
    Huang, Zhi-yu
    Yu, Hai-feng
    Wu, Feng-qin
    [J]. ACTA PHARMACOLOGICA SINICA, 2010, 31 (06) : 746 - 752
  • [34] Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations
    Hughes, DA
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1655 - 1655
  • [35] Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
    Yun Fan
    Neng-ming Lin
    Sheng-lin Ma
    Lü-hong Luo
    Luo Fang
    Zhi-yu Huang
    Hai-feng Yu
    Feng-qin Wu
    [J]. Acta Pharmacologica Sinica, 2010, 31 : 746 - 752
  • [36] Quality of life in non-small cell lung cancer patients receiving gemcitabine (Gemzar®) plus cisplatin or etoposide plus cisplatin
    Rosell, R
    Cardenal, F
    Montes, A
    Artal, A
    Carrato, A
    Lomas, M
    Alberola, V
    Barnetto, I
    Massuti, B
    Liepa, AM
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 84 - 84
  • [37] Safety and Resource Utilization by Non-small Cell Lung Cancer Histology Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaive Patients with Advanced Non-small Cell Lung Cancer
    Novello, Silvia
    Pimentel, Francisco Luis
    Douillard, Jean-Yves
    O'Brien, Mary
    von Pawel, Joachim
    Eckardt, John
    Liepa, Astra M.
    Simms, Lorinda
    Visseren-Grul, Carla
    Paz-Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1602 - 1608
  • [38] Cost-effectiveness of Gemcitabine (Gemzar™) plus cisplatin versus etoposide plus cisplatin for advanced non small cell lung cancer (NSCLC) in Spain
    Rosell, R
    Sacristan, JA
    Duthie, T
    Cardenal, F
    Artal, A
    Carrato, A
    Lomas, M
    Barneto, I
    Bameto, I
    Massuti, B
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 92 - 93
  • [39] Chemotherapy with gemcitabine plus cisplatin in the treatment of locally advanced non-small cell lung cancer (NSCLC): a Brazilian study of 84 patients
    Ismael, Gustavo V.
    Beato, Carlos A.
    Coradazzi, Ana Lucia
    Budin, Jose Valfredo
    Moraes Neto, Francisco A.
    Nunes, Adauto J.
    Segaila, Jose Getulio M.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 175 - 175
  • [40] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Masuda, Takeshi
    Fujitaka, Kazunori
    Doi, Mihoko
    Awaya, Yoshikazu
    Kuyama, Shoichi
    Kitaguchi, Soichi
    Ueda, Kazuhiro
    Hattori, Noboru
    Okada, Morihito
    [J]. BMC CANCER, 2018, 18
12345